On the other hand, clinical studies using an IL-1 receptor antagonist in ALS patients have not shown a significant reduction in disease progression (Maier et al., 2015), suggesting that inflammasome activation does not play a major role in ALS, or that the pathology is driven by IL-18 or by DAMPs via pyroptosis. Here, IL18 is linked to amyotrophic lateral sclerosis.